ABBVIE

FDA criticizes AbbVie's Ubrelvy ad featuring Serena Williams for overstating drug's efficacy, demanding immediate ad halt or Ubrelvy distribution stop. AbbVie halts ad airing and complies with FDA investigation.

The United States RNA Polymerase Inhibitor Market is projected to reach USD xx.x billion by 2031, driven by advancements in clinical diagnostics and precision medicine. Key players include Johnson & Johnson, AstraZeneca, and Pfizer. Market segments include types like Veliparib and applications in hospital, retail, and online pharmacies. Regional analysis highlights North America's dominance, Europe's strategic alliances, and Asia-Pacific's growing energy demand.

80% of glaucoma patients on prostaglandin analogs (PGAs) have Grade 2-3 meibomian gland dysfunction (MGD), worsening ocular surface disease (OSD). Benzalkonium chloride (BAK) in chronic drops disrupts tear film stability. Symptoms like redness and tearing can lead to poor medication compliance and glaucoma progression. Innovative non-preserved or non-BAK glaucoma medications, sustained-release drug delivery systems, and non-drug treatments like selective laser trabeculoplasty (SLT) or minimally invasive glaucoma surgeries (MIGS) offer solutions. Preservative-free drops and procedural interventions aim to mitigate MGD and OSD effects.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Oncternal Therapeutics discontinues clinical trials for ONCT-534 and ONCT-808, leading to a 60% stock drop and 37% workforce reduction to save cash.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

John joins Trialbee for its global team, industry-leading patient recruitment platform, and Swedish culture, aiming to contribute to equity in clinical research.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.